Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Yuji Nozaki, Yasuaki Nagare, Chisato Ashida, Daisuke Tomita, Akinori Okada, Asuka Inoue, Koji Kinoshita, Masanori Funauchi & Itaru Matsumura. (2018) Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results. Biologics: Targets and Therapy 12, pages 171-182.
Read now
Read now
Roy Fleischmann, John A. Goldman, Marjatta Leirisalo-Repo, Ellen Zanetakis, Hisham El-Kadi, Herbert Kellner, Rebecca Bolce, Raphael DeHoratius, Jim Wang & Dennis Decktor. (2014) Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study. Current Medical Research and Opinion 30:11, pages 2139-2149.
Read now
Read now
Machaon M.K. Bonafede, Shravanthi R. Gandra, Kathleen M. Fox & Kathleen L. Wilson. (2012) Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. Journal of Medical Economics 15:4, pages 635-643.
Read now
Read now
M Neovius, A Sundström, JF Simard, B Wettermark, T Cars, N Feltelius, J Askling & L Klareskog. (2011) Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scandinavian Journal of Rheumatology 40:1, pages 8-15.
Read now
Read now
Zsolt B Nagy, Mónika Csanád, Katalin Tóth, Balázs Börzsönyi, Csaba Demendi, János Rigó Jr & József Gábor Joó. (2010) Current concepts in the genetic diagnostics of rheumatoid arthritis. Expert Review of Molecular Diagnostics 10:5, pages 603-618.
Read now
Read now
H. M. Habib, T. E. Taher, D. A. Isenberg & R. A. Mageed. (2009) Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha. Scandinavian Journal of Rheumatology 38:2, pages 112-120.
Read now
Read now
Articles from other publishers (13)
Mondana H. Ghias, Andrew D. Johnston, Allison J. Kutner, Robert G. Micheletti, H. Dean Hosgood & Steven R. Cohen. (2020) High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. Journal of the American Academy of Dermatology 82:5, pages 1094-1101.
Crossref
Crossref
Thierry Schaeverbeke, Marie-Elise Truchetet, Marie Kostine, Thomas Barnetche, Bernard Bannwarth & Christophe Richez. (2016) Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology 55:2, pages 210-220.
Crossref
Crossref
Rafael Ferriols-Lisart & Francisco Ferriols-Lisart. (2015) Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatology International 35:7, pages 1193-1210.
Crossref
Crossref
D. E. Furst, S. A. Shaikh, M. Greenwald, B. Bennett, O. Davies, K. Luijtens, F. Staelens, W. Koetse & P. Bertin. (2015) Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis. Arthritis Care & Research 67:2, pages 151-160.
Crossref
Crossref
B. Glintborg, B. Gudbjornsson, N. Steen Krogh, E. Omerovic, N. Manilo, M. Holland-Fischer, H. M. Lindegaard, A. Gitte Loft, H. Nordin, L. Johnsen, S. Flejsborg Oeftiger, A. Hansen, C. Rasmussen, G. Grondal, A. Jon Geirsson & M. Lund Hetland. (2014) Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. Rheumatology 53:11, pages 2100-2109.
Crossref
Crossref
Adam J. Luber, Cindy L. Tsui, Gillian M. Heinecke, Mark G. Lebwohl & Jacob O. Levitt. (2014) Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. Journal of the American Academy of Dermatology 70:3, pages 525-532.
Crossref
Crossref
Rieke Alten & Filip van den Bosch. (2014) Dose optimization of infliximab in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases 17:1, pages 5-18.
Crossref
Crossref
Ingrid Lekander, Fredrik Borgström, Jörgen Lysholm, Ronald F. van Vollenhoven, Staffan Lindblad, Pierre Geborek & Gisela Kobelt. (2012) The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. The European Journal of Health Economics 14:6, pages 863-873.
Crossref
Crossref
Tiina Levälampi, Markku Korpela, Katriina Vuolteenaho & Eeva Moilanen. (2009) Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years’ drug survival. Rheumatology International 30:12, pages 1611-1620.
Crossref
Crossref
M. Blom, W. Kievit, H. H. Kuper, T. L. Jansen, H. Visser, A. A. den Broeder, H. L. M. Brus, M. A. F. J. van de Laar & P. L. C. M. van Riel. (2010) Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care & Research 62:9, pages 1335-1341.
Crossref
Crossref
M. Schmalzing. (2009) Effekt der Dosissteigerung von Infliximab bei rheumatoider ArthritisEffect of increasing the infliximab dose in rheumatoid arthritis. Zeitschrift für Rheumatologie 69:5, pages 450-453.
Crossref
Crossref
Gino Vena, Francesco Loconsole, Valentina Mastrandrea, Rosalba Buquicchio & Nicoletta Cassano. (2010) Therapeutic Hotline: Re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab: a retrospective analysis. Dermatologic Therapy 23:2, pages 199-202.
Crossref
Crossref
L. E. Kristensen, P. Geborek & T. Saxne. (2008) Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register. Rheumatology 48:3, pages 243-245.
Crossref
Crossref